Page last updated: 2024-10-20

pyridoxal and Friedreich Ataxia

pyridoxal has been researched along with Friedreich Ataxia in 1 studies

Friedreich Ataxia: An autosomal recessive disease, usually of childhood onset, characterized pathologically by degeneration of the spinocerebellar tracts, posterior columns, and to a lesser extent the corticospinal tracts. Clinical manifestations include GAIT ATAXIA, pes cavus, speech impairment, lateral curvature of spine, rhythmic head tremor, kyphoscoliosis, congestive heart failure (secondary to a cardiomyopathy), and lower extremity weakness. Most forms of this condition are associated with a mutation in a gene on chromosome 9, at band q13, which codes for the mitochondrial protein frataxin. (From Adams et al., Principles of Neurology, 6th ed, p1081; N Engl J Med 1996 Oct 17;335(16):1169-75) The severity of Friedreich ataxia associated with expansion of GAA repeats in the first intron of the frataxin gene correlates with the number of trinucleotide repeats. (From Durr et al, N Engl J Med 1996 Oct 17;335(16):1169-75)

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's1 (100.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Richardson, DR1
Mouralian, C1
Ponka, P1
Becker, E1

Other Studies

1 other study available for pyridoxal and Friedreich Ataxia

ArticleYear
Development of potential iron chelators for the treatment of Friedreich's ataxia: ligands that mobilize mitochondrial iron.
    Biochimica et biophysica acta, 2001, May-31, Volume: 1536, Issue:2-3

    Topics: Animals; Drug Design; Friedreich Ataxia; Iron; Iron Chelating Agents; Iron Radioisotopes; Isoniazid;

2001